BCL2 and MYC dual-hit lymphoma/leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Translocations involving the BCL2 gene (18q21.3) and MYC gene (8q24) are key drivers in B-cell lymphomas.
• BCL2 translocation, typically t(14;18), inhibits apoptosis, while MYC translocation, often t(8;14), accelerates cell proliferation.
• Dual-hit lymphoma (DHL) arises when both BCL2 and MYC genes undergo translocation within the same cell, leading to aggressive disease.

Purpose of the Study:

• To review the clinicopathological features of BCL2 and MYC dual-hit lymphoma/leukemia (DHL).
• To summarize current knowledge on the diagnosis, characteristics, and prognosis of DHL.
• To highlight the poor outcomes associated with DHL despite current treatment strategies.

Main Methods:

• Literature review of studies on BCL2 and MYC translocations in B-cell malignancies.
• Analysis of clinicopathological data from diagnosed cases of DHL.
• Synthesis of information regarding diagnostic criteria, clinical presentation, and treatment outcomes.

Main Results:

• DHL accounts for approximately 2% of all B-cell malignancies.
• Common translocations include BCL2-IGH and MYC-IGH, with variations in IG light chain involvement.
• DHL is characterized by elevated LDH, B symptoms, advanced stage, extranodal and CNS involvement, and a poor prognosis.

Conclusions:

• DHL represents a distinct and aggressive subtype of B-cell lymphoma.
• The combination of BCL2 and MYC translocations confers a particularly poor prognosis.
• Further research into novel therapeutic strategies is crucial for improving outcomes in DHL patients.